Shanghai Pharmaceuticals Holding Co Class H ((SHPMF)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Shanghai Pharmaceuticals Holding Co. is conducting a Phase II clinical study titled ‘A Multicenter, Open, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH5030 Tablets in Subjects With Her2-positive/Mutated Biliary Tract OR Colorectal Cancer.’ The study aims to assess the effectiveness and safety of SPH5030 tablets for patients with these specific cancer types, potentially offering a new treatment avenue for a challenging condition.
Intervention/Treatment: The study is testing SPH5030, an experimental drug administered orally at a dosage of 600mg daily. This intervention targets Her2-positive or mutated biliary tract and colorectal cancers, aiming to improve patient outcomes.
Study Design: This is an interventional study with a single-group assignment. There is no masking involved, meaning all participants and researchers know the treatment being administered. The primary purpose is to evaluate the treatment’s efficacy.
Study Timeline: The study began on May 23, 2024, with the latest update submitted on August 15, 2025. These dates are crucial as they indicate the study’s progression and current recruitment status, which is ongoing.
Market Implications: The progress of this study could positively influence Shanghai Pharmaceuticals’ stock performance by enhancing investor confidence in the company’s innovative capabilities. As the company advances in cancer treatment, it may gain a competitive edge in the pharmaceutical industry, potentially impacting market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.